DOCSLIB.ORG

Tafamidis for Transthyretin Familial Polyneuropathy (TTR-FAP) Evidence Review Group Assessment of Manufacturer Submission

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Tafamidis for Transthyretin Familial Polyneuropathy (TTR-FAP) Evidence Review Group Assessment of Manufacturer Submission Tafamidis for Transthyretin Familial Polyneuropathy (TTR-FAP) Evidence Review Group assessment of manufacturer submission Produced by CRD/CHE Technology Assessment Group (Centre for Reviews and Dissemination/Centre for Health Economics), University of York Authors Rita Faria, Research Fellow; Simon Walker, Research Fellow; Stephen Palmer, Professor Centre for Health Economics Mark Corbett, Research Fellow; Lisa Stirk, Information Specialist; Catriona McDaid, Senior Research Fellow. Centre for Reviews & Dissemination Acknowledgements With thanks to Professor Philip Hawkins and Professor Mary Reilly who provided clinical advice to the ERG. With thanks to David Epstein for providing advice on the health economics. Date completed 16th July 2012 Declared competing interests of the authors None Page | 1 Table of Contents 1 SUMMARY ..................................................................................................................... 11 1.1 Scope of the Evidence Review Group assessment .................................................. 11 1.2 Scope of the manufacturer submission .................................................................... 11 1.3 Summary of submitted clinical effectiveness evidence ............................................ 11 1.4 Summary of submitted cost effectiveness evidence ................................................. 12 1.5 Summary of additional work undertaken by the ERG ............................................... 14 1.6 Commentary on the robustness of submitted evidence ........................................... 15 2 BACKGROUND .............................................................................................................. 20 2.1 Introduction.............................................................................................................. 20 2.2 Description of health problem .................................................................................. 20 2.2.1 Epidemiology .................................................................................................... 20 2.2.2 Clinical variability in TTR-FAP .......................................................................... 21 2.2.3 V30M mutation ................................................................................................. 21 2.2.4 Stages of disease progression in V30M ............................................................ 21 2.2.5 Heterogeneity within V30M populations ............................................................ 22 2.2.6 Non-V30M mutations ........................................................................................ 23 2.2.7 Applicability of Coutinho classification of disease stages to NonV30M and non- endemic V30M populations ............................................................................................ 23 2.3 Current treatment .................................................................................................... 24 2.3.1 Treatment of symptoms .................................................................................... 24 2.3.2 Liver transplantation ......................................................................................... 24 2.4 Tafamidis and treatments in development ............................................................... 26 3 THE DECISION PROBLEM ............................................................................................ 27 3.1 Population ............................................................................................................... 27 3.2 Intervention.............................................................................................................. 27 3.3 Comparators ............................................................................................................ 27 3.4 Outcomes ................................................................................................................ 28 3.5 Time frame .............................................................................................................. 28 3.6 Treatment strategies ................................................................................................ 28 4 CLINICAL EFFECTIVENESS ......................................................................................... 29 4.1 Overview of the manufacturer’s submission............................................................. 29 4.2 ERG systematic review............................................................................................ 30 4.3 Overview of included studies ................................................................................... 31 4.4 Randomised Controlled Trial (Fx-005) ..................................................................... 33 Page | 2 4.4.1 Objectives and methods ................................................................................... 33 4.4.2 Analyses ........................................................................................................... 33 4.4.3 Results ............................................................................................................. 36 4.4.4 Assessment of study quality ............................................................................. 43 4.4.5 FDA analyses of the RCT data ......................................................................... 48 4.5 Open-label extension study (Fx-006) ....................................................................... 49 4.5.1 Study details and main results .......................................................................... 49 4.6 Non-randomised studies .......................................................................................... 52 4.6.1 Pre-post study (Fx1A-201)................................................................................ 53 4.6.2 Case series ...................................................................................................... 55 4.7 Ongoing studies ...................................................................................................... 56 4.8 Generalisability of the study results ......................................................................... 56 4.9 Summary ................................................................................................................. 57 5 ECONOMIC EVALUATION ............................................................................................ 59 5.1. Overview of manufacturer’s economic evaluation .................................................... 59 5.1.1. Review of existing literature .............................................................................. 64 5.1.2. Reports of other Health Technology Assessment agencies on tafamidis .......... 64 5.1.3. Manufacturer’s ‘de novo’ economic evaluation ................................................. 64 5.2. Patient population .................................................................................................... 68 5.3. Natural history ......................................................................................................... 70 5.3.1 Disease severity and TQoL scores ................................................................... 70 5.3.2 Mortality ............................................................................................................ 77 5.3.3 Liver transplantation ......................................................................................... 81 5.4 Treatment effectiveness within the submission ........................................................ 84 5.5 Health related quality of life ..................................................................................... 88 5.5.1 HRQoL associated with TTR-FAP .................................................................... 88 5.5.2 HRQoL associated with liver transplantation .................................................... 92 5.5.3 HRQoL experienced by carers ......................................................................... 93 5.5.4 HRQoL: Final issues ......................................................................................... 93 5.6 Resources and costs ............................................................................................... 94 5.6.1 Acquisition costs of tafamidis ............................................................................ 94 5.6.2 Costs associated with healthcare resource use per disease stage ................... 95 5.6.3 Costs associated with healthcare resource use from liver transplantation ........ 96 5.6.4 Productivity costs accrued by patients and carers ............................................ 96 5.7 Sensitivity analyses ................................................................................................. 97 5.8 Model validation ...................................................................................................... 97 Page | 3 5.9 Results included in manufacturer’s submission ....................................................... 98 5.9.1 Base-case ........................................................................................................ 98 5.9.2 Sensitivity Analysis ........................................................................................... 99 5.9.3 Budget Impact considerations ........................................................................ 100 5.10 Summary of uncertainties and issues .................................................................... 103 6 ADDITIONAL
Load more

Recommended publications
  • Specialty Pipeline Monthly Update
    Specialty Pipeline Monthly Update Critical updates in an ever changing environment May 2019 New drug information ● Skyrizi™ (risankizumab-rzaa): AbbVie’s Skyrizi, a biologic that selectively blocks interleukin-23 (IL-23) received U.S. Food and Drug Administration (FDA) approval for the treatment of moderate-to- severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It will directly compete with Janssen’s Tremfya® and Sun’s Illumya® in this market space as well as with other biologic drugs commonly used for plaque psoriasis (i.e., AbbVie’s Humira®, Novartis’ Cosentyx®, and J&J’s Stelara®). Skyrizi has an annual wholesale acquisition cost (WAC) of $88,500 for the first year which includes loading doses, and $59,000 yearly thereafter. AbbVie notes this is cheaper than most widely prescribed biologic treatment for moderate to severe plaque psoriasis.1 ● Eticovo™ (etanercept-ykro): The second biosimilar referencing Amgen/Pfizer’s Enbrel® (etanercept) was approved by the FDA for Samsung Bioepis’ Eticovo for the treatment of certain patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis; psoriatic arthritis; ankylosing spondylitis and plaque psoriasis. Sandoz’s Erelzi is also a biosimilar referencing Enbrel. Neither Samsung Bioepis or Sandoz have released their launch plans; however, depending on patent litigation Enbrel could lose exclusivity either in 2019 or 2029. ● Vyndaqel® (tafamidis meglumine) and Vyndamax™ (tafamidis): Pfizer received FDA approval for both Vyndaqel and Vyndamax, for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular- related hospitalization. The FDA approved dose is either Vyndamax 61 mg (1 capsule) once daily, or Vyndaqel 80 mg (four-20 mg capsules) once daily, both achieve the same effectiveness in cardiomyopathy.
    [Show full text]
  • May 2019 New Drugs
    May 2019 Learn more New drugs Drug name Therapeutic category Indication(s) Launch information Manufacturer(s) ® Dengvaxia For the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. Dengvaxia is approved for use in (dengue tetravalent vaccine, Vaccine individuals 9 through 16 years of age with laboratory- TBD live)* confirmed previous dengue infection and living in endemic Sanofi Pasteur areas. Ingrezza® (valbenazine) Vesicular monoamine initiation pack Treatment of adults with tardive dyskinesia April 22, 2019 transporter-2 inhibitor Neurocrine Biosciences ® Nayzilam (midazolam)† Acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive single-dose nasal spray Benzodiazepine TBD seizures) that are distinct from a patient’s usual seizure UCB pattern in patients with epilepsy 12 years of age and older In combination with Faslodex® (fulvestrant) for the treatment ® of postmenopausal women, and men, with hormone receptor- Piqray (alpelisib)* Phosphoinositide 3-kinase CA positive, human epidermal growth factor receptor 2-negative, May 30, 2019 Novartis inhibitor PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen 1 RxHighlights May 2019 Drug name Therapeutic category Indication(s) Launch information Manufacturer(s) ® Qternmet XR Sodium-glucose cotransporter 2 (dapagliflozin/saxagliptin/ Adjunct to diet and exercise to improve glycemic control in inhibitor/dipeptidyl
    [Show full text]
  • Foldrx Pharmaceuticals, a Pfizer Company a Multicenter, International, Phase 3, Double-Blind, Placebo-Controlled, Randomized
    PF-06291826 Tafamidis Meglumine B3461028 Final Protocol Amendment 3, 24 May 2016 FOLDRX PHARMACEUTICALS, A PFIZER COMPANY A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM) Compound: PF-06291826 Compound Name: tafamidis US IND Number: IND 71,880 European Clinical Trial Database 2012-002465-35 (EudraCT) Number: Protocol Number: B3461028 Phase: 3 Page 1 PF-06291826 Tafamidis Meglumine B3461028 Final Protocol Amendment 3, 24 May 2016 Document History Document Version Date Summary of Changes Original protocol 31 Jul 2013 N/A Amendment 1 16 Apr 2014 Following initiation of the study the following changes were made to the study protocol: 1. Typographical corrections and clarifications. 2. Added the results of the B3461031 study indicating a lack of tafamidis effect on QTc. 3. Clarified the target sample size as 400 subjects. 4. Added “Smoking and Alcohol Classification” to the Schedule of Activities. 5. Removed Serum Amyloid A from required Screening analysis as it is an indicator of an active inflammatory process and does not contribute to defining an appropriate subject for this study. 6. Amended the Week 2 follow-up to allow for flexibility in scheduling a visit to either the investigator’s clinic or their primary care physician’s office or a visit to a local laboratory for blood collection (which would also include, a phone call). 7. The second 6MWT during Screening was removed in order to ease the burden of site visits.
    [Show full text]
  • CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
    CDER Breakthrough Therapy Designation Approvals Data as of December 31, 2020 Total of 190 Approvals Submission Application Type and Proprietary Approval Use Number Number Name Established Name Applicant Date Treatment of patients with previously BLA 125486 ORIGINAL-1 GAZYVA OBINUTUZUMAB GENENTECH INC 01-Nov-2013 untreated chronic lymphocytic leukemia in combination with chlorambucil Treatment of patients with mantle cell NDA 205552 ORIGINAL-1 IMBRUVICA IBRUTINIB PHARMACYCLICS LLC 13-Nov-2013 lymphoma (MCL) Treatment of chronic hepatitis C NDA 204671 ORIGINAL-1 SOVALDI SOFOSBUVIR GILEAD SCIENCES INC 06-Dec-2013 infection Treatment of cystic fibrosis patients age VERTEX PHARMACEUTICALS NDA 203188 SUPPLEMENT-4 KALYDECO IVACAFTOR 21-Feb-2014 6 years and older who have mutations INC in the CFTR gene Treatment of previously untreated NOVARTIS patients with chronic lymphocytic BLA 125326 SUPPLEMENT-60 ARZERRA OFATUMUMAB PHARMACEUTICALS 17-Apr-2014 leukemia (CLL) for whom fludarabine- CORPORATION based therapy is considered inappropriate Treatment of patients with anaplastic NOVARTIS lymphoma kinase (ALK)-positive NDA 205755 ORIGINAL-1 ZYKADIA CERITINIB 29-Apr-2014 PHARMACEUTICALS CORP metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients NDA 206545 ORIGINAL-1 ZYDELIG IDELALISIB GILEAD SCIENCES INC 23-Jul-2014 for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
    [Show full text]
  • Long-Term Safety and Efficacy of Tafamidis for the Treatment of Hereditary Transthyretin Amyloid Polyneuropathy: Results up to 6 Years
    AMYLOID, 2017 VOL. 24, NO. 3, 194–204 https://doi.org/10.1080/13506129.2017.1357545 ORIGINAL ARTICLE Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years Fabio A. Barrosoa, Daniel P. Judgeb, Ben Ebedec, Huihua Lic, Michelle Stewartc, Leslie Amassc and Marla B. Sultanc aDepartment of Neurology, Institute for Neurological Research Raul Carrea, FLENI, Buenos Aires, Argentina; bJohns Hopkins University Center for Inherited Heart Disease, Baltimore, MD, USA; cPfizer Inc, New York, NY, USA ABSTRACT ARTICLE HISTORY Background: The objective of the present study was to evaluate the long-term safety and efficacy of Received 22 November 2016 tafamidis in treating hereditary transthyretin amyloid polyneuropathy. Revised 13 July 2017 Methods: A prospectively planned interim analysis was conducted on an on-going, phase III, open-label Accepted 17 July 2017 extension study following an 18-month, randomized, controlled study and 12-month, open-label exten- KEYWORDS sion study in ATTRV30M patients and a single-arm, open-label study in non-ATTRV30M patients. Thirty- Amyloidosis; disease- seven ATTRV30M patients received placebo for 18 months, then switched to tafamidis and 38 ATTRV30M modifying drug; non- patients and 18 non-ATTRV30M patients continuously received tafamidis from day 1, up to 6 years. ATTRV30M; ATTRV30M Results: Long-term tafamidis was associated with a favourable safety/tolerability profile, without any unexpected adverse events. Patients initiating tafamidis at the start of the randomized study had less polyneuropathy progression versus those switching to tafamidis following 18 months of placebo and were less likely to progress to the next ambulatory stage after up to 6 years follow-up.
    [Show full text]
  • 211172Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 211172Orig1s000 CLINICAL REVIEW(S) Combined Clinical/Biostatistical Review Clinical Reviewer – Breder; Statistical Reviewer – Massie NDA 211172 Tegsedi (inotersen) CLINICAL REVIEW Application Type Original NDA Application Number(s) 211172 Priority or Standard Priority Submit Date(s) 11/6/17 Received Date(s) 11/6/17 PDUFA Goal Date 10/6/18 (Extension); 7/6/18 (Original) Division/Office DNP/ODEI Reviewer Name(s) Clinical Reviewer – Christopher Breder; Statistical Reviewer – Tristan Massie Review Completion Date October 4, 2018 Established/Proper Name Inotersen (Proposed) Trade Name Tegsedi Applicant Ionis Pharmaceuticals, Inc. Dosage Form(s) 284 mg inotersen (300 mg sodium salt)/ 1.5 mL in a single- dose, prefilled syringe including a safety syringe device. Applicant Proposed (b) (4) Dosing Regimen(s) doses should be administered once every week (b) (4) Applicant Proposed For treatment of adult patients with hereditary TTR amyloidosis Indication(s)/Population(s) with polyneuropathy (hATTR-PN) (b) (4) Recommendation on Substantial evidence of effectiveness has been provided Regulatory Action Recommended For treatment of the polyneuropathy of hereditary transthyretin- Indication(s)/Population(s) mediated amyloidosis (if applicable) 1 Reference ID: 4330479 Combined Clinical/Biostatistical Review Clinical Reviewer – Breder; Statistical Reviewer – Massie NDA 211172 Tegsedi (inotersen) Table of Contents Glossary .........................................................................................................................................
    [Show full text]
  • VYNDAQEL Are Not Substitutable on a Per Mg Basis
    HIGHLIGHTS OF PRESCRIBING INFORMATION • VYNDAMAX and VYNDAQEL are not substitutable on a per mg basis. These highlights do not include all the information needed to use (2.1) VYNDAQEL and VYNDAMAX safely and effectively. See full prescribing information for VYNDAQEL and VYNDAMAX. --------------------- DOSAGE FORMS AND STRENGTHS --------------------­ Capsules: Tafamidis meglumine 20 mg and tafamidis 61 mg. (3) VYNDAQEL® (tafamidis meglumine) capsules, for oral administration Initial U.S. Approval: 2019 ------------------------------ CONTRAINDICATIONS -----------------------------­ None. (4) VYNDAMAXTM (tafamidis) capsules, for oral administration Initial U.S. Approval: 2019 To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. --------------------------- INDICATIONS AND USAGE ---------------------------­ VYNDAQEL and VYNDAMAX are transthyretin stabilizers indicated for the ----------------------- USE IN SPECIFIC POPULATIONS ----------------------­ treatment of the cardiomyopathy of wild type or hereditary • Pregnancy: Based on animal studies, may cause fetal harm. (8.1) transthyretin-mediated amyloidosis in adults to reduce cardiovascular • Lactation: Advise not to breastfeed. (8.2) mortality and cardiovascular-related hospitalization. (1) See 17 for PATIENT COUNSELING INFORMATION and ----------------------- DOSAGE AND ADMINISTRATION ----------------------­ FDA-approved patient labeling. The recommended dosage is either: Revised: 05/2019 • VYNDAQEL 80 mg orally once
    [Show full text]
  • Design and Rationale of the Phase 3 Tafamidis in Transthyretin Cardiomyopathy
    Design and Rationale of the Phase 3 Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) Mathew S. Maurer, MD; Perry Elliott, MD; Giampaolo Merlini, PhD; Sanjiv J. Shah, MD; Márcia Waddington Cruz, MD; Alison Flynn, BSN; Balarama Gundapaneni, MAS; Carolyn Hahn, BA; Steven Riley, PharmD, PhD; Jeffrey Schwartz, PhD; Marla B. Sultan, MD, MBA; Claudio Rapezzi, MD; on behalf of the ATTR-ACT Study Investigators From Columbia University College of Physicians and Surgeons, New York, NY (M.S.M); University College London, London, UK (P.E); IRCCS Policlinico San Matteo and University of Pavia, Pavia, Italy (G.M.); Northwestern University, Chicago, IL (S.J.S); Federal University of Rio de Janeiro, National Amyloidosis Referral Center, CEPARM, Rio de Janeiro, Brazil (M.W.C.); Pfizer Inc, Collegeville, PA (A.F., C.H.); inVentiv Health, Burlington, MA (B.G.); Pfizer Inc, Groton, CT (S.R., J.S.); Pfizer Inc, New York, NY (M.B.S); and the University of Bologna, Bologna, Italy (C.R). Correspondence to Mathew S. Maurer, MD, Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE), Columbia University Medical Center, Allen Hospital of New York Presbyterian Hospital, 5141 Broadway, 3 Field W, Room 035, New York, NY 10034 . E-mail [email protected] Running head (49/50 characters with spaces max): Maurer et al Tafamidis in TTR-CM Clinical Trial Word count ~5688 (max 6000 words; includes title page, abstract, text, references, tables, and figure legends) References 49 (max 50) Transthyretin cardiomyopathy (TTR-CM) is a rare,
    [Show full text]
  • Mrx CLINICAL ALERT
    MRx JUNE 2019 CLINICAL ALERT YOUR MONTHLY SOURCE FOR DRUG INFORMATION HIGHLIGHTS HOT TOPIC: completed 2-year START trial (n=12, GENE THERAPY APPROVED therapeutic cohort). Both studies EDITORIAL FOR SPINAL MUSCULAR enrolled patients with SMA type 1. ATROPHY Treatment with Zolgensma led to STAFF significant improvement in reaching The United States (US) Food and developmental motor milestones, Drug Administration (FDA) approved such as head control, sitting without EDITOR IN CHIEF onasemnogene abeparvovec-xioi support, and/or standing/walking ® Maryam Tabatabai (Zolgensma ) for the treatment of without assistance compared to the PharmD patients < 2 years of age with spinal natural history of the disease. A durable muscular atrophy (SMA) who have effect of nearly 4 years was reported bi-allelic mutations in the survival in the START long-term follow-up. EXECUTIVE EDITOR motor neuron 1 (SMN1) gene, which Zolgensma carries a Boxed warning Carole Kerzic instructs production of a protein critical for acute serious liver injury. RPh for motor neuron function. SMA is the leading genetic cause of infant Avexis/Novartis set a wholesale DEPUTY EDITORS mortality. The most common form, SMA acquisition cost (WAC) of $2.125 million Jill Bot type 1, occurs in about 1 in 10,000 for the 1-time Zolgensma dose, making PharmD newborns, leading to about 500 new it the world’s most expensive drug. cases per year in the US. Patients with The Institute for Clinical and Economic Stephanie Christofferson SMA type 1 experience progressive Review (ICER) published a value-based PharmD motor function decline beginning price benchmark for Zolgensma of $1.2 shortly after birth.
    [Show full text]
  • Wednesday, June 12, 2019 4:00Pm
    Wednesday, June 12, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – June 12, 2019 DATE: June 5, 2019 Note: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the June meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/Use of Angiotensin Converting Enzyme Inhibitor (ACEI)/ Angiotensin Receptor Blocker (ARB) Therapy in Patients with Diabetes and Hypertension (HTN) Mailing Update – Appendix B Action Item – Vote to Prior Authorize Aldurazyme® (Laronidase) and Naglazyme® (Galsulfase) – Appendix C Action Item – Vote to Prior Authorize Plenvu® [Polyethylene Glycol (PEG)-3350/Sodium Ascorbate/Sodium Sulfate/Ascorbic Acid/Sodium Chloride/Potassium Chloride] – Appendix D Action Item – Vote to Prior Authorize Consensi® (Amlodipine/Celecoxib) and Kapspargo™ Sprinkle [Metoprolol Succinate Extended-Release (ER)] – Appendix E Action Item – Vote to Update the Prior Authorization Criteria For H.P. Acthar® Gel (Repository Corticotropin Injection) – Appendix F Action Item – Vote to Prior Authorize Fulphila® (Pegfilgrastim-jmdb), Nivestym™ (Filgrastim-aafi),
    [Show full text]
  • 2016 Medicines in Development for Rare Diseases a LIST of ORPHAN DRUGS in the PIPELINE
    2016 Medicines in Development for Rare Diseases A LIST OF ORPHAN DRUGS IN THE PIPELINE Autoimmune Diseases Product Name Sponsor Official FDA Designation* Development Status Actemra® Genentech treatment of systemic sclerosis Phase III tocilizumab South San Francisco, CA www.gene.com Adempas® Bayer HealthCare Pharmaceuticals treatment of systemic sclerosis Phase II riociguat Whippany, NJ www.pharma.bayer.com ARA 290 Araim Pharmaceuticals treatment of neuropathic pain in patients Phase II Tarrytown, NY with sarcoidosis www.ariampharma.com ARG201 arGentis Pharmaceuticals treatment of diffuse systemic sclerosis Phase II (type 1 native bovine skin Collierville, TN www.argentisrx.com collagen) BYM338 Novartis Pharmaceuticals treatment of inclusion body myositis Phase III (bimagrumab) East Hanover, NJ www.novartis.com CCX168 ChemoCentryx treatment of anti-neutrophil cytoplasmic Phase II (5a receptor antagonist) Mountain View, CA auto-antibodies associated vasculitides www.chemocentryx.com (granulomatosis with polyangitis or Wegener's granulomatosis), microscopic polyangitis, and Churg-Strauss syndrome * This designation is issued by the FDA's Office of Orphan Products Development while the drug is still in development. The designation makes the sponsor of the drug eligible for entitlements under the Orphan Drug Act of 1983. The entitlements include seven years of marketing exclusivity following FDA approval of the drug for the designated use. Medicines in Development: Rare Diseases | 2016 1 Autoimmune Diseases Product Name Sponsor Official FDA
    [Show full text]
  • Efficacy of Patisiran in Patients with Hattr
    Efficacy of Patisiran in Patients with hATTR Amyloidosis and Prior Tafamidis Use: Analysis of APOLLO Hollis Lin1, Laura Obici2, Violaine Planté-Bordeneuve3, Matthew T White1, Richard Riese1, and Ole B Suhr4 1Alnylam Pharmaceuticals, Cambridge, USA; 2Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 3Henri Mondor Hospital-Assistance Publique-East Université Paris-Est Créteil, Paris, France; 4Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden • The key secondary endpoint was the change from baseline in the Figure 4. Change in mNIS+7 from Baseline to 18 Months Introduction Norfolk Quality of Life Diabetic Neuropathy questionnaire (Norfolk QOL-DN) score at 18 months 40 Placebo Patisiran Hereditary Transthyretin-Mediated (hATTR) Amyloidosis – Norfolk QOL-DN is a 35-item QOL questionnaire sensitive to 35 28.0 small-fiber, large-fiber, and autonomic nerve function; higher (22.8, 33.1) • Rare, progressively debilitating, and fatal disease caused by a 30 mutation in the transthyretin (TTR) gene that results in multisystem score indicates worsening in QOL (range: −4 to 136) 20.8 accumulation of amyloid fibrils (e.g., in nerves, heart, and • Previous TTR tetramer stabilizer use (diflunisal or tafamidis) vs no 25 (13.1, 28.5) gastrointestinal tract) and subsequent dysfunction across these previous stabilizer use was a stratification factor at randomization 20 multiple organs1–5 • Patients with prior tafamidis use were required to discontinue Worse • Affects ~50,000 people worldwide4; median survival of 4.7 years
    [Show full text]